The rapidity (onset within 24 hours) and magnitude (50%-75% clinical response rate, even in treatment-resistant patients) of the efficacy of ketamine suggest that it can be a new and important role in the treatment of mood disorders where clinical response is needed urgently or where there has been inadequate response to other treatments.

Disclosure: Dr. Krystal is a co-proponent of a use patent related to the intranasal administration of ketamine for the treatment of depression that has been licensed by Johnson and Johnson.

References
1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351–4. PubMed PMID: 10686270.
2. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016 Mar 3;22(3):238–49. doi: 10.1038/nm.4050. PubMed PMID: 26937618.
3. Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2013 Jun 15;73(12):1133–41. doi: 10.1016/j.biopsych.2013.03.026. Review. PubMed PMID: 23726151; PubMed Central PMCID: PMC3671489.